Innoviva, Inc.
Close on Oct 19, 2026
- Market cap
- $1.55B
- P/E (TTM)
- 5.2
- Dividend yield
- –
About Innoviva
Pharmaceutical Preparations, SIC 2834
Innoviva, Inc. is a biopharmaceutical company that manages a portfolio of royalty-bearing medicines, critical care therapies, and healthcare assets. Its business focuses on two primary areas: commercializing specialty treatments and licensing respiratory medications. The company’s partnered portfolio includes respiratory drugs RELVAR/BREO ELLIPTA and ANORO ELLIPTA. Through its critical care and infectious disease platform, Innoviva provides hospital-focused therapies such as GIAPREZA for distributive shock, XACDURO for bacterial pneumonia, XERAVA for intra-abdominal infections, ZEVTERA for severe bacterial conditions, and NUZOLVENCE for gonorrhea. These products serve healthcare institutions, medical professionals, and patients being treated for acute infections, respiratory conditions, and critical illnesses.
The company is headquartered in Burlingame, California. Its commercial operations and approved pharmaceuticals span international markets, including the United States, Europe, the United Kingdom, and several Asian jurisdictions such as China, Hong Kong, Singapore, and Taiwan. Innoviva distributes its therapies through wholly owned subsidiaries as well as regional commercial partners across North America, Europe, and the Asia-Pacific region.
Summary of the business section of Innoviva's latest annual report, written by StockData.
Company profile
Company
- Legal name
- Innoviva, Inc.
- Founded
- 1996
- Headquarters
- Burlingame, CA
- Address
- 1350 Old Bayshore Highway, Suite 400 94010
- Phone
- (650) 238-9600
- Employees
- 159, Dec 31, 2025
- Industry
- Pharmaceutical Preparations
- Incorporated in
- Delaware
- Fiscal year ends
- December 31
- Auditor
- Deloitte & Touche LLP, San Jose, CA
Stock & identifiers
- Ticker
- INVA
- Exchange
- Nasdaq
- Shares outstanding
- 72M, Jul 31, 2026
- Public float
- $1.26B, Jun 30, 2025
- Filer category
- Large accelerated filer
- SEC CIK
- 1080014
- CUSIP
- 45781M101
- ISIN
- US45781M1018
- LEI
- 549300ACOX4QTBES6535
- EIN
- 94-3265960
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Pavel Raifeld | Chief Executive Officer, Director | 284,799 |
| Stephen Basso | Chief Financial Officer | 88,013 |
| Marianne Zhen | Chief Accounting Officer | 56,389 |
| Josephine Linden | Director | 15,194 |
| Derek A. Small | Director | 45,035 |
| Sarah J. Schlesinger | Director | 140,492 |
| Mark DiPaolo | Director | 140,492 |
| Jules Haimovitz | Director | 152,692 |
CEO pay and shareholder return
Pay versus performance table from the proxy statement
| Fiscal year | CEO total pay | CEO pay actually paid | Other executives (avg) | Value of $100 invested | Peer group |
|---|---|---|---|---|---|
| FY2025 Mr. Raifeld | $5.40M | $6.12M | $1.63M | $161 | $116 |
| FY2024 Mr. Raifeld | $2.72M | $3.09M | $1.02M | $140 | $88 |
| FY2024 Pavel Raifeld | $2.72M | $3.09M | $1.02M | $140 | $88 |
| FY2023 Mr. Raifeld | $868.65K | $1.06M | $1.13M | $129 | $94 |
| FY2023 Pavel Raifeld | $868.65K | $1.06M | $1.13M | $129 | $94 |
| FY2022 Mr. Raifeld | $1.80M | $7.13K | $665.25K | $107 | $90 |
“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.
Employees
Headcount reported in annual reports
“As of December 31, 2025, we had 159 employees, all of whom were full-time employees.”
Corporate history
Events identified from SEC filings